In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CSL buys Talecris for $3.1bn in cash and debt; withdrawn

Executive Summary

Australian hemostasis therapeutics developer CSL has agreed to pay $3.1bn--$1.9bn in cash and $1.2bn in net debt--to acquire privately held Talecris Biotherapeutics (critical care treatments in the areas of immunology, hemostasis, and pulmonology).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies